BRONCHO SALINE Drug Patent Profile

When do Broncho Saline patents expire, and when can generic versions of Broncho Saline launch?

Broncho Saline is a drug marketed by Blairex and is included in one NDA.

The generic ingredient in BRONCHO SALINE is sodium chloride. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the sodium chloride profile page.

Summary for BRONCHO SALINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	39
DailyMed Link:	BRONCHO SALINE at DailyMed

Recent Clinical Trials for BRONCHO SALINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
OM Pharma	Phase 4
People's Hospital of Anshun City of Guizhou Province	Phase 2/Phase 3
Sandoz	Phase 3

See all BRONCHO SALINE clinical trials

US Patents and Regulatory Information for BRONCHO SALINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Blairex	BRONCHO SALINE	sodium chloride	AEROSOL, METERED;INHALATION	019912-001	Sep 3, 1992		DISCN	Yes	No

Market Dynamics and Financial Trajectory for BRONCHO SALINE

---

Summary
BRONCHO SALINE, a medical solution primarily used for respiratory therapies, has seen varying market dynamics influenced by technological advancements, regulatory landscapes, and healthcare demand shifts. Its financial trajectory over recent years reflects broader industry trends in respiratory treatments, compounded by regional adoption rates and product formulations. This analysis offers a comprehensive overview of the current market environment, budget allocations, competitive positioning, and future growth projections for BRONCHO SALINE within the global pharmaceutical sector.

---

What is BRONCHO SALINE?

BRONCHO SALINE is a saline-based respiratory solution designed to facilitate mucus clearance and maintain airway patency, especially in patients with chronic obstructive pulmonary disease (COPD), cystic fibrosis, or post-surgical respiratory care. Typically supplied via nebulizers or instillation devices, it serves as an adjunct or standalone therapy, targeting hospitals, clinics, and home healthcare markets.

Product Composition & Specifications:	Parameter	Details
Active Ingredient	Normal saline (0.9% Sodium Chloride)
Formulation	Sterile solution, pre-packaged
Delivery Methods	Nebulizers, inhalers, syringes
Packaging	Single-use vials, multidose bottles

What Are the Key Market Drivers?

Multiple factors fuel BRONCHO SALINE's market expansion:

• Rising Respiratory Disease Prevalence:
  The global burden of COPD (over 300 million cases worldwide, WHO, 2022), cystic fibrosis, and asthma escalates demand for mucolytic and saline therapies.

• Increased Adoption of Pulmonary Care Protocols:
  Hospitals and clinics are emphasizing airway clearance therapies, favoring solutions like BRONCHO SALINE.

• Home Healthcare Expansion:
  Rising at-home respiratory management propels demand for portable nebulization solutions.

• Innovation & Product Development:
  Formulation enhancements, such as preservative-free solutions, broaden clinical utility.

• Regulatory Approvals & Reimbursement Policies:
  Favorable policies, especially in North America and Europe, support market growth.

What Are the Market Challenges and Constraints?

• Generic Competition & Price Erosion:
  Widespread availability of saline solutions, including generics, pressures pricing strategies.

• Regulatory Hurdles:
  Stringent approvals for new formulations or delivery devices can delay commercialization.

• Limited Patent Protection:
  Generally low or no patent barriers for saline solutions reduce exclusivity and investments.

• Market Penetration Barriers:
  Adoption varies across regions due to differences in healthcare infrastructure and reimbursement.

How Has the Regional Market Evolved?

Region	Market Size (USD Million, 2022)	Key Drivers	Challenges
North America	450	High chronic respiratory disease prevalence, advanced healthcare infrastructure	Reimbursement constraints, commoditized market
Europe	320	Growing respiratory therapy use, aging population	Regulatory variations, price sensitivity
Asia-Pacific	210	Increasing respiratory disease cases, rising healthcare access	Market fragmentation, low awareness
Rest of World	70	Emerging healthcare development, infectious disease burden	Limited regulatory frameworks, affordability

Source: Market research reports [1][2].

What Are the Key Players and Competitive Landscape?

Company	Product Portfolio	Market Share (Est.)	Strategic Focus
Medtronic	Commercial nebulizers & saline solutions	35%	Innovation in inhalation device tech
Baxter International	Sterile saline products	25%	Expanded distribution channels
Novartis	Respiratory therapeutics	15%	Integrating saline therapy combos
Local/Niche Manufacturers	Generic saline solutions	25%	Cost competitiveness

Competitive Challenges:

• Product differentiation is limited due to similar formulations.
• Regulatory approval cycles are lengthy and cost-intensive.

What Is the Financial Trajectory of BRONCHO SALINE?

Historical Revenue Trends

Last updated: January 7, 2026

Year	Estimated Revenue (USD Million)	% Growth Year-over-Year	Key Factors
2018	200	—	Initial market penetration
2019	220	10%	Increased adoption, expanded use
2020	250	13.6%	COVID-19 pandemic booster demand
2021	275	10%	New regional entries
2022	300	9.1%	Market saturation in mature regions

Forecast (Next 5 Years):

Year	Projected Revenue (USD Million)	CAGR	Assumptions
2023	330	10%	Increased adoption in emerging markets
2024	365	10.5%	Product reformulations and device integrations
2025	402	10.4%	Expansion in home healthcare markets
2026	443	10.2%	Regulatory approvals, increased clinical trials
2027	487	10%	Integration into bundled respiratory care packages

Note: These projections reflect current market trends and assume no significant regulatory or economic disruptions.

What Are Future Growth Opportunities?

• Emerging Markets: Rapid urbanization and aging populations present untapped potential.
• Product Innovation: Developing combined therapies (saline + mucolytics) and smart nebulizers.
• Digital Health Integration: Remote monitoring and compliance tracking to enhance efficacy.
• Regulatory Approvals: Streamlining approvals for expanded indications and formulations.

Comparison with Alternative Respiratory Therapies

Therapy Type	Efficacy	Cost	Delivery Method	Market Penetration
Saline Solution	Mucus hydration, airway clearing	Low	Nebulizers, inhalers, syringes	High in primary respiratory care
Mucolytics	Thinner mucus, improved clearance	Moderate	Nebulizers	Niche, adjunct therapy
Bronchodilators	Airway dilation, symptom relief	Moderate to high	Inhalers, nebulizers	Broad, with entrenched market
Antibiotics (Inhaled)	Infection control	High	Nebulizers	Limited to infection-specific cases

BRONCHO SALINE remains a foundational, low-cost therapy with high utility, especially in primary and homecare settings.

---

Key Takeaways

• Market Growth is Driven by Increasing Respiratory Diseases & Aging Populations: The world faces a rising burden of chronic respiratory conditions, supporting steady demand for saline solutions like BRONCHO SALINE.

• Regional Variations Impact Market Strategies: North America and Europe dominate, but significant growth opportunities exist in Asia-Pacific and emerging markets.

• Competitive Landscape is Fragmented: Market share is distributed among multinational corporations and local manufacturers, with low product differentiation.

• Financial Trajectory Shows a Healthy CAGR (~10%) over the next five years: This rebound is supported by product innovations and expanded healthcare access.

• Opportunities exist in product differentiation and digital health integration: Future growth hinges on technological advances and regulatory facilitation.

---

FAQs

Q1: How does BRONCHO SALINE compare cost-wise to other respiratory therapies?
A: Saline solutions like BRONCHO SALINE are typically among the most affordable respiratory treatments, primarily because of their simple formulation and widespread availability, making them accessible in both developed and developing markets.

Q2: What are the regulatory hurdles associated with BRONCHO SALINE?
A: As a saline-based solution, it generally faces fewer regulatory challenges than new pharmaceutical agents. However, specific formulations or delivery devices may require approval from agencies like the FDA or EMA, which can involve stability, safety, and efficacy evaluations.

Q3: Which regions are expected to see the fastest growth for BRONCHO SALINE?
A: Asia-Pacific and Latin America are projected to experience the fastest CAGR due to increasing healthcare investments, rising respiratory disease burdens, and expanding distribution networks.

Q4: How are technological innovations impacting BRONCHO SALINE's market?
A: Integration with smart nebulizer devices enables better patient compliance, remote monitoring, and optimized therapy, thereby enhancing market appeal.

Q5: What role does reimbursement play in expanding BRONCHO SALINE's market?
A: Favorable reimbursement policies in major markets like North America and Europe facilitate widespread adoption, especially in home healthcare settings.

---

References:

1. Global Respiratory Market Report, MarketWatch, 2022.
2. WHO Report on Respiratory Diseases, 2022.